287 related articles for article (PubMed ID: 11396235)
1. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
2. Serum chromogranin A in monitoring metastatic prostate cancer patients.
Tarle M
Anticancer Res; 1999; 19(6C):5663-6. PubMed ID: 10697637
[TBL] [Abstract][Full Text] [Related]
3. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
Tarle M; Ahel MZ; Kovacić K
Anticancer Res; 2002; 22(4):2525-9. PubMed ID: 12174956
[TBL] [Abstract][Full Text] [Related]
4. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
5. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
7. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
9. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
11. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
12. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
Kobayashi M; Kuramoto H; Ota J; Fujimoto N
Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
14. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment.
Maffezzini M; Simonato A; Fortis C
Prostate; 1996 May; 28(5):282-6. PubMed ID: 8610053
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
16. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
17. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
[TBL] [Abstract][Full Text] [Related]
18. Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer.
Pintér O; Molnár J; Tóth C; Szabó Z; Lipták J; Fél P; Papp G; Hollman E; Hazay L; Streit B; Kisbenedek L; Fehér M; Kocsis I; Pajor L
In Vivo; 2005; 19(4):787-92. PubMed ID: 15999550
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
20. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
Ahel MZ; Kovacic K; Tarle M
Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
